Anti-inflammatory and anti-nociceptive activities of Ganoderma lucidum occurring in South India

Pharmaceutical Biology

Volumn 41, Issue 4, 2003, Pages 301-304

  Sheena, N ^a   Ajith, T A ^a   Janardhanan, K K ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Anti inflammatory; Anti nociceptive; Ganoderma lucidum; Medicinal mushroom

Indexed keywords

ACETIC ACID ETHYL ESTER; ANTIINFLAMMATORY AGENT; ANTINOCICEPTIVE AGENT; CARRAGEENAN; DICLOFENAC; FORMALDEHYDE; GANODERMA LUCIDUM EXTRACT; METHANOL; PLANT EXTRACT;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CHEMICAL REACTION; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENCY; GANODERMA LUCIDUM; INDIA; INHIBITION KINETICS; ISOLATION PROCEDURE; MALE; MOUSE; NONHUMAN; STATISTICAL SIGNIFICANCE; TROPICS;

ANIMALIA; BASIDIOMYCOTA; GANODERMA; GANODERMA LUCIDUM;

EID: 0041385975     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1076/phbi.41.4.301.15677     Document Type: Article

References (17)

1. Ajith TA, Janardhanan KK (2001): Antioxidant and anti-inflammatory activities of methanol extract of Phellinus rimosus (Berk) Pilat. Indian J Exp Biol 39: 1166-1169.
2. Brooks PM, Day RO (1991): Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 324: 1716-1719.
3. Chen AW (2001): Cultivation of the medicinal mushroom Ganoderma lucidum (Curt.:Fr) P. Karst. Reishi in North America. Mushroom World Dec: 1-9.
4. Collins T (1999): Acute and chronic inflammation. In: Cotran RS, Kumar V, Collins T, eds., Textbook of Robbins Pathologic Basis of Disease. 6th ed., Philadelphia, W.B. Sounders Company, pp. 50-51.
5. de Souza MM, Madeira A, Berti C, Krough R, Yunes RA, Cechinel-Filho V (2000): Anti-nociceptive properties of the methanolic extract obtained from Ipomoea pes-caprae (L.) R. Br. J Ethnopharmacol 69: 85-90.
6. Greenwald RA (1991): Animal model for evaluation of arthritic drugs. Meth Find Clin Pharmacol 13: 75-83.
7. Hwang S, Lam M, Li C, Shen T (1986): Release of platelet activating factor and its involvement in the firt phase of carrageenan rat foot oedema. Eur J Pharmacol 120: 33-41.
8. Jong SC, Birmingham JM (1992): Medicinal benefits of the mushroom Ganoderma. Adv Appl Microbiol 37: 101-134.
9. Kim HW, Kim BK (1999): Biomedical triterpenoids of Ganoderma lucidum (Curt.:Fr.) P. Karst (Aphyllophoromycetideae). Int J Med Mushr 1: 121-138.
10. Koyama K, Imaizumi T, Akiba M, Kinoshita K, Takahashi K, Suzuki A, Yano S, Horie S, Watanabe K, Naoi Y (1997): Anti-nociceptive components of Ganoderma lucidum. Planta Med 63: 224-227.
11. Larsen GL, Henson PM (1983): Mediators of inflammation. Ann Rev Immunol 1: 335-339.
12. Liu GT (1999): Recent advances in research of pharmacology and clinical application of Ganoderma P. Karst species (Aphyllophoromycetideae) in China. Inter J Med Mushr 1: 63-67.
13. Lo TN, Almeida AP, Beaven MA (1982): Dextran and carrageenan evoke different inflammatory response in rat with respect to composition of infiltrates and effect of indometacin. J Pharmacol Exp Ther 221: 261-267.
14. Nishitoba T, Salo H, Shirasu S, Sakamura S (1986): Evidence on the strain specific terpenoid pattern of Ganoderma lucidum. Agric Biol Chem 50: 2151-2154.
15. Shiao MS, Lee KK, Lin LJ, Wang CT (1994): Natural products and biological activities of the Chinese medicinal fungus Ganoderma lucidum. In: Ho CT, Osawa T, Huang MT, Roem RT, eds., Food Phytochemicals II. Teas, Spices and Herbs. Washington DC American Chemical Society, pp. 342-354.
16. Vane J, Booting R (1987): Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1: 89-96.
17. Wheeler-Aceto H, Cowan A (1991): Neurogenic and tissue mediated components of formalin-induced oedema. Agents Actions 34: 264-268.